Search clinical trials for: fallopian cancer

Total 86296 results

Sun Yat-sen University
Hutchmed

Recruiting

Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer

Ovarian Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer | Ovarian Carcinoma | Fallopian Tube Carcinosarcoma

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8

United States
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
OncoC4, Inc.
Merck Sharp & Dohme LLC; GOG Foundation

Recruiting

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer (PRESERVE-004)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | High Grade Serous Adenocarcinoma of Ovary

United States
ImmunoGen, Inc.
GOG Foundation

Recruiting

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Korea, Republic of, Spain, Australia, Canada, United Kingdom, Italy, Czechia, Philippines, Israel, Belgium
Memorial Sloan Kettering Cancer Center

Recruiting

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer | Stage II Ovary Cancer | Stage II Ovarian Cancer | Stage III Ovary Cancer and other conditions

United States
AstraZeneca

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

Advanced Solid Malignancies

United States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
Ohio State University Comprehensive Cancer Center

Recruiting

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Mucinous Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Primary Peritoneal Endometrioid... and other conditions

United States
Yonsei University
CanariaBio Inc.

Recruiting

Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Korea, Republic of
The Netherlands Cancer Institute

Recruiting

Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer (CisCon)

Fallopian Tube Carcinoma | Peritoneal Cancer | FIGO Stage III Ovarian Cancer

Netherlands
Mersana Therapeutics

Recruiting

A Study of XMT-1660 in Participants With Solid Tumors

Breast Cancer | Adenoid Cystic Carcinoma | Ovarian Cancer | Fallopian Tube Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Primary Peritoneal Cavity Cancer

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Ovarian Cancer
M.D. Anderson Cancer Center

Recruiting

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ovarian Cancer | Fallopian Tube Cancer

United States
Genelux Corporation
GOG Foundation

Recruiting

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Platinum-refractory Ovarian Cancer | Primary Peritoneal Cancer | High-grade Serous Ovarian Cancer | Endometrioid Ovarian Cancer | Ovarian Clear Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

Ovarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian Tube High Grade Serous Adenocarcinoma | Primary Peritoneal Endometrioid Adenocarcinoma | Stage III Fallopian... and other conditions

United States
TILT Biotherapeutics Ltd.
Merck Sharp & Dohme LLC

Recruiting

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA)

Platinum-resistant Ovarian Cancer | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Refractory Fallopian Tube Carcinoma | Platinum-Refractory Primary Peritoneal Carcinoma | Platinum-refractory Ovarian Carcinoma | Platinum-Sensitive Ovarian... and other conditions

United States, Finland
Charite University, Berlin, Germany
Kliniken Essen-Mitte

Recruiting

KORE-Innovation: a Prospective, Multi-site Clinical Trial to Implement and Analyse the Effects of an Innovative Perioperative Care Pathway to Reduce Complications for Patients With Ovarian Cancer (KORE)

Fallopian Tube Cancer | Frailty | Ovary Cancer | Peritoneum Cancer

Germany
Incyte Corporation

Recruiting

Study of INCB123667 in Subjects With Advanced Solid Tumors

Solid Tumors

United States, Japan, France, Italy, United Kingdom, Netherlands, Switzerland
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
National Cancer Institute, Naples

Recruiting

MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer (MITO 35a)

Ovarian Cancer

Italy
Roswell Park Cancer Institute
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditions

United States
Rutgers, The State University of New Jersey

Recruiting

Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer

Cervical Cancer | Gynecologic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Uterine Cancer

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Carcinoma

United States, France
Shanghai Gynecologic Oncology Group
Fudan University

Not yet recruiting

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma

China
Sutro Biopharma, Inc.

Recruiting

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Ovarian Carcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States
Seagen Inc.

Recruiting

A Study of SGN-B7H4V in Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung | Adenoid Cystic Carcinoma | Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms | Endometrial Neoplasms | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Carcinoma | HER2 Negative Breast Neoplasms | Hormone Receptor Positive Breast Neoplasms

United States, Spain, Canada, United Kingdom, Germany, Italy
Tempus AI

Recruiting

Tempus Priority Study: A Pan-tumor Observational Study

Lymphoma | Leukemia | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Fallopian Tube Cancer | Lung Cancer | Prostate Cancer | Brain Cancer | Bladder Cancer | Cancer of Head and Neck | Peritoneal Cancer | Cancer of Liver | Cancer of Stomach | Cancer of Cervix | Cancer of Colon | Cancer of Rectum | Cancer of Gastrointestinal... and other conditions

United States
K-Group, Beta, Inc., a wholly owned subsidiary...

Recruiting

A Study of ZN-c3 in Subjects With High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

United States, Australia, France, Poland
AGO Research GmbH
GlaxoSmithKline

Not yet recruiting

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Primary Peritoneal Cancer | Recurrent Ovarian Cancer | Recurrent Fallopian Tube Cancer
M.D. Anderson Cancer Center

Recruiting

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...

United States
M.D. Anderson Cancer Center

Recruiting

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

Malignant Solid Neoplasm | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage... and other conditions

United States
Mural Oncology, Inc
Merck Sharp & Dohme LLC

Recruiting

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (ARTISTRY-7)

Fallopian Tube Cancer | Platinum-resistant Ovarian Cancer | Primary Peritoneal Cancer

United States, Spain, Korea, Republic of, Taiwan, Canada, Israel, France, United Kingdom, Germany, Belgium, Czechia, Singapore, Australia, Austria, Italy
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense; Sharp Clinical Services, Inc

Recruiting

Using Aspirin to Improve Immunological Features of Ovarian Tumors

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University College, London
Barts & The London NHS Trust; Anticancer Fund, Belgium; JP Moulton Charitable...

Recruiting

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer (ACTOv)

Ovarian Cancer | Fallopian Tube Cancer | Relapsed Ovarian Cancer | Peritoneal Cancer | High Grade Serous Carcinoma | Ovary Cancer | Endometrioid Carcinoma

United Kingdom
Haider Mahdi
Pfizer; Zenith Epigenetics

Recruiting

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States
University Health Network, Toronto
GlaxoSmithKline

Recruiting

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | High Grade Serous Cancer | High Grade Endometrioid Cancer

Canada
Guardant Health, Inc.

Recruiting

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE)

Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Fallopian Tube Carcinoma | Endometrial Carcinoma | Bladder Carcinoma | Esophageal Carcinoma | Invasive Breast Carcinoma | Cutaneous Melanoma | Epithelial Ovarian... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Stage IIIC Fallopian Tube Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IIIC Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Advanced Ovarian Carcinoma

United States
OncXerna Theraputics, Inc.

Not yet recruiting

A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma
Xencor, Inc.
ICON plc

Recruiting

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Ovarian Cancer | Endometrial Cancer | Cervical Carcinoma | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Clear Cell Carcinoma

United States
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma and other conditions

United States
Pfizer

Not yet recruiting

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Cervical Cancer | Metastatic Colorectal Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer | Primary Peritoneal Cancer | Metastatic Kidney Cancer
Lee's Pharmaceutical Limited

Not yet recruiting

A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Hospices Civils de Lyon

Recruiting

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer (PIPACOVA)

Peritoneal Carcinomatosis | Stage IV Fallopian Tube Cancer | Stage IV Ovarian Cancer | Metastatic Ovarian Carcinoma | Metastatic Malignant Neoplasm in the Peritoneum | Stage III Ovarian Cancer | Stage III Fallopian Tube Cancer

France
Wenjun Cheng

Not yet recruiting

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Neoplasms by Histologic Type | Neoplasms by Site | Carcinoma | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Endocrine System Diseases | Ovarian Diseases | Ovarian Neoplasms | Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Angiogenesis | Genital Diseases, Female | Antineoplastic... and other conditions
Massachusetts General Hospital
Johns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaborators

Recruiting

Developing a Test for the Detection of Ovarian Cancer

Ovarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditions

United States

Search clinical trials for: fallopian cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations